Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
Rangering i aksjer #26767
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Aksjekurs
$1.30
Sist synkronisert: 2023-10-13
Markedsverdi
$38.02M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Zynerba Pharmaceuticals, Inc. (ZYNE)

Kategori

P/B-forhold for Zynerba Pharmaceuticals, Inc. (ZYNE)
P/B-forhold per 2026 TTM: 0
Ifølge Zynerba Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Zynerba Pharmaceuticals, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter